Literature DB >> 20472828

B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance.

Jang-June Park1, Ryusuke Omiya, Yumiko Matsumura, Yukimi Sakoda, Atsuo Kuramasu, Mathew M Augustine, Sheng Yao, Fumihiko Tsushima, Hidehiko Narazaki, Sudarshan Anand, Yingjia Liu, Scott E Strome, Lieping Chen, Koji Tamada.   

Abstract

T-cell tolerance is the central program that prevents harmful immune responses against self-antigens, in which inhibitory PD-1 signal given by B7-H1 interaction plays an important role. Recent studies demonstrated that B7-H1 binds CD80 besides PD-1, and B7-H1/CD80 interaction also delivers inhibitory signals in T cells. However, a role of B7-H1/CD80 signals in regulation of T-cell tolerance has yet to be explored. We report here that attenuation of B7-H1/CD80 signals by treatment with anti-B7-H1 monoclonal antibody, which specifically blocks B7-H1/CD80 but not B7-H1/PD-1, enhanced T-cell expansion and prevented T-cell anergy induction. In addition, B7-H1/CD80 blockade restored Ag responsiveness in the previously anergized T cells. Experiments using B7-H1 or CD80-deficient T cells indicated that an inhibitory signal through CD80, but not B7-H1, on T cells is responsible in part for these effects. Consistently, CD80 expression was detected on anergic T cells and further up-regulated when they were re-exposed to the antigen (Ag). Finally, blockade of B7-H1/CD80 interaction prevented oral tolerance induction and restored T-cell responsiveness to Ag previously tolerized by oral administration. Taken together, our findings demonstrate that the B7-H1/CD80 pathway is a crucial regulator in the induction and maintenance of T-cell tolerance.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20472828      PMCID: PMC2938239          DOI: 10.1182/blood-2010-01-265975

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  51 in total

1.  Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells.

Authors:  Monica V Goldberg; Charles H Maris; Edward L Hipkiss; Andrew S Flies; Lijie Zhen; Rubin M Tuder; Joseph F Grosso; Timothy J Harris; Derese Getnet; Katharine A Whartenby; Dirk G Brockstedt; Thomas W Dubensky; Lieping Chen; Drew M Pardoll; Charles G Drake
Journal:  Blood       Date:  2007-03-28       Impact factor: 22.113

2.  B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells.

Authors:  Takeshi Azuma; Sheng Yao; Gefeng Zhu; Andrew S Flies; Sarah J Flies; Lieping Chen
Journal:  Blood       Date:  2008-01-25       Impact factor: 22.113

3.  Programmed death 1 ligand signaling regulates the generation of adaptive Foxp3+CD4+ regulatory T cells.

Authors:  Li Wang; Karina Pino-Lagos; Victor C de Vries; Indira Guleria; Mohamed H Sayegh; Randolph J Noelle
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-02       Impact factor: 11.205

4.  Tag SNP screening of the PDCD1 gene for association with Graves' disease.

Authors:  P R Newby; E L Roberts-Davies; O J Brand; J M Heward; J A Franklyn; S C L Gough; M J Simmonds
Journal:  Clin Endocrinol (Oxf)       Date:  2007-05-09       Impact factor: 3.478

5.  Interaction between B7-H1 and PD-1 determines initiation and reversal of T-cell anergy.

Authors:  Fumihiko Tsushima; Sheng Yao; Tahiro Shin; Andrew Flies; Sarah Flies; Haiying Xu; Koji Tamada; Drew M Pardoll; Lieping Chen
Journal:  Blood       Date:  2007-02-08       Impact factor: 22.113

6.  Interaction of human PD-L1 and B7-1.

Authors:  Manish J Butte; Victor Peña-Cruz; Mi-Jung Kim; Gordon J Freeman; Arlene H Sharpe
Journal:  Mol Immunol       Date:  2008-06-27       Impact factor: 4.407

7.  Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.

Authors:  Manish J Butte; Mary E Keir; Theresa B Phamduy; Arlene H Sharpe; Gordon J Freeman
Journal:  Immunity       Date:  2007-07-12       Impact factor: 31.745

8.  Involvement of the programmed death-1/programmed death-1 ligand pathway in CD4+CD25+ regulatory T-cell activity to suppress alloimmune responses.

Authors:  Yusuke Kitazawa; Masayuki Fujino; Quanxing Wang; Hiromitsu Kimura; Miyuki Azuma; Masato Kubo; Ryo Abe; Xiao-Kang Li
Journal:  Transplantation       Date:  2007-03-27       Impact factor: 4.939

9.  Tissue expression of PD-L1 mediates peripheral T cell tolerance.

Authors:  Mary E Keir; Spencer C Liang; Indira Guleria; Yvette E Latchman; Andi Qipo; Lee A Albacker; Maria Koulmanda; Gordon J Freeman; Mohamed H Sayegh; Arlene H Sharpe
Journal:  J Exp Med       Date:  2006-04-10       Impact factor: 14.307

10.  PD-L1 regulates the development, maintenance, and function of induced regulatory T cells.

Authors:  Loise M Francisco; Victor H Salinas; Keturah E Brown; Vijay K Vanguri; Gordon J Freeman; Vijay K Kuchroo; Arlene H Sharpe
Journal:  J Exp Med       Date:  2009-12-14       Impact factor: 14.307

View more
  143 in total

Review 1.  Cell surface signaling molecules in the control of immune responses: a tide model.

Authors:  Yuwen Zhu; Sheng Yao; Lieping Chen
Journal:  Immunity       Date:  2011-04-22       Impact factor: 31.745

Review 2.  The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer.

Authors:  Leora Horn; Martin Reck; David R Spigel
Journal:  Oncologist       Date:  2016-06-27

3.  Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications.

Authors:  Zhixue Zheng; Zhaode Bu; Xijuan Liu; Lianhai Zhang; Ziyu Li; Aiwen Wu; Xiaojiang Wu; Xiaojing Cheng; Xiaofang Xing; Hong Du; Xiaohong Wang; Ying Hu; Jiafu Ji
Journal:  Chin J Cancer Res       Date:  2014-02       Impact factor: 5.087

4.  PD-L1 mediated the differentiation of tumor-infiltrating CD19+ B lymphocytes and T cells in Invasive breast cancer.

Authors:  Honggeng Guan; Yang Lan; Yuqiu Wan; Qin Wang; Cheng Wang; Longjiang Xu; Yongjing Chen; Wenting Liu; Xueguang Zhang; Yecheng Li; Yongping Gu; Zemin Wang; Fang Xie
Journal:  Oncoimmunology       Date:  2015-08-12       Impact factor: 8.110

5.  A soluble form of CD80 enhances antitumor immunity by neutralizing programmed death ligand-1 and simultaneously providing costimulation.

Authors:  Samuel T Haile; Lucas A Horn; Suzanne Ostrand-Rosenberg
Journal:  Cancer Immunol Res       Date:  2014-04-02       Impact factor: 11.151

Review 6.  Mechanisms of action of therapeutic antibodies for cancer.

Authors:  J M Redman; E M Hill; D AlDeghaither; L M Weiner
Journal:  Mol Immunol       Date:  2015-04-23       Impact factor: 4.407

7.  B7H1/CD80 interaction augments PD-1-dependent T cell apoptosis and ameliorates graft-versus-host disease.

Authors:  Ruishu Deng; Kaniel Cassady; Xiaofan Li; Sheng Yao; Mingfeng Zhang; Jeremy Racine; Jeffrey Lin; Lieping Chen; Defu Zeng
Journal:  J Immunol       Date:  2014-12-08       Impact factor: 5.422

Review 8.  Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors.

Authors:  Manuela Terranova-Barberio; Scott Thomas; Pamela N Munster
Journal:  Immunotherapy       Date:  2016-06       Impact factor: 4.196

Review 9.  Role of the PD-1 pathway in the immune response.

Authors:  L V Riella; A M Paterson; A H Sharpe; A Chandraker
Journal:  Am J Transplant       Date:  2012-08-17       Impact factor: 8.086

Review 10.  Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation.

Authors:  Miguel F Sanmamed; Lieping Chen
Journal:  Cancer J       Date:  2014 Jul-Aug       Impact factor: 3.360

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.